Key result
An evidence-based review of therapeutic options for prehypertension highlights a paucity of evidence for intervening in these patients despite their increased cardiovascular risk.
Why the study?
What are the evidence-based therapeutic options for patients with prehypertension?
What are the evidence-based therapeutic options for patients with prehypertension?
This review discusses evidence-based therapeutic options for patients with prehypertension, a group at increased risk for cardiovascular morbidity and mortality.
Cautions against routine intervention in prehypertension; leaves open whether dedicated trials can define benefit.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) defines hypertension as systolic blood pressure (BP) ≥140 mmHg or diastolic BP ≥90 mmHg. The JNC-7 defines 'prehypertension' to include systolic BP values between 120 and 139 mmHg and diastolic BP values between 80 and 89 mmHg. Individuals with blood pressure in the prehypertension range are clearly at increased risk of developing hypertension in the future and have an increased risk of cardiovascular morbidity and mortality, compared with those with normal BP. However, there is paucity of evidence to intervene in these patients. In this article we discuss an evidence-based approach to therapeutic options in patients with prehypertension.
No takes yet. Share an insight, caveat, or question.
Gaddam et al. (2011) conducted a review in Prehypertension. Antihypertensive therapy vs. Alternative therapeutic options was evaluated. An evidence-based review of therapeutic options for prehypertension highlights a paucity of evidence for intervening in these patients despite their increased cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: